Your browser doesn't support javascript.
loading
The pan-cancer lncRNA PLANE regulates an alternative splicing program to promote cancer pathogenesis.
Teng, Liu; Feng, Yu Chen; Guo, Su Tang; Wang, Pei Lin; Qi, Teng Fei; Yue, Yi Meng; Wang, Shi Xing; Zhang, Sheng Nan; Tang, Cai Xia; La, Ting; Zhang, Yuan Yuan; Zhao, Xiao Hong; Gao, Jin Nan; Wei, Li Yuan; Zhang, Didi; Wang, Jenny Y; Shi, Yujie; Liu, Xiao Ying; Li, Jin Ming; Cao, Huixia; Liu, Tao; Thorne, Rick F; Jin, Lei; Shao, Feng-Min; Zhang, Xu Dong.
Affiliation
  • Teng L; Translational Research Institute, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Academy of Medical Science, Zhengzhou University, Henan, China.
  • Feng YC; School of Medicine and Public Health, The University of Newcastle, Callaghan, NSW, Australia.
  • Guo ST; Department of Molecular Biology, Shanxi Cancer Hospital and Institute, Shanxi, China.
  • Wang PL; Translational Research Institute, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Academy of Medical Science, Zhengzhou University, Henan, China.
  • Qi TF; Translational Research Institute, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Academy of Medical Science, Zhengzhou University, Henan, China.
  • Yue YM; Translational Research Institute, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Academy of Medical Science, Zhengzhou University, Henan, China.
  • Wang SX; Translational Research Institute, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Academy of Medical Science, Zhengzhou University, Henan, China.
  • Zhang SN; Translational Research Institute, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Academy of Medical Science, Zhengzhou University, Henan, China.
  • Tang CX; Translational Research Institute, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Academy of Medical Science, Zhengzhou University, Henan, China.
  • La T; School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia.
  • Zhang YY; School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia.
  • Zhao XH; School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia.
  • Gao JN; Department of Breast Surgery, Shanxi Bethune Hospital, Shanxi, China.
  • Wei LY; Department of Breast Surgery, Shanxi Bethune Hospital, Shanxi, China.
  • Zhang D; Orthopaedics Department, John Hunter Hospital, Hunter New England Health, New Lambton, NSW, Australia.
  • Wang JY; Children's Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, NSW, Australia.
  • Shi Y; Department of Pathology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan, China.
  • Liu XY; Translational Research Institute, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Academy of Medical Science, Zhengzhou University, Henan, China.
  • Li JM; Translational Research Institute, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Academy of Medical Science, Zhengzhou University, Henan, China.
  • Cao H; Department of Nephrology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan, China.
  • Liu T; Translational Research Institute, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Academy of Medical Science, Zhengzhou University, Henan, China.
  • Thorne RF; Children's Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, NSW, Australia.
  • Jin L; Translational Research Institute, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Academy of Medical Science, Zhengzhou University, Henan, China.
  • Shao FM; School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia.
  • Zhang XD; Translational Research Institute, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Academy of Medical Science, Zhengzhou University, Henan, China. Lei.Jin@newcastle.edu.au.
Nat Commun ; 12(1): 3734, 2021 06 18.
Article in En | MEDLINE | ID: mdl-34145290
Genomic amplification of the distal portion of chromosome 3q, which encodes a number of oncogenic proteins, is one of the most frequent chromosomal abnormalities in malignancy. Here we functionally characterise a non-protein product of the 3q region, the long noncoding RNA (lncRNA) PLANE, which is upregulated in diverse cancer types through copy number gain as well as E2F1-mediated transcriptional activation. PLANE forms an RNA-RNA duplex with the nuclear receptor co-repressor 2 (NCOR2) pre-mRNA at intron 45, binds to heterogeneous ribonucleoprotein M (hnRNPM) and facilitates the association of hnRNPM with the intron, thus leading to repression of the alternative splicing (AS) event generating NCOR2-202, a major protein-coding NCOR2 AS variant. This is, at least in part, responsible for PLANE-mediated promotion of cancer cell proliferation and tumorigenicity. These results uncover the function and regulation of PLANE and suggest that PLANE may constitute a therapeutic target in the pan-cancer context.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gene Expression Regulation, Neoplastic / Alternative Splicing / RNA, Long Noncoding / Neoplasms Type of study: Etiology_studies Limits: Humans Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2021 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gene Expression Regulation, Neoplastic / Alternative Splicing / RNA, Long Noncoding / Neoplasms Type of study: Etiology_studies Limits: Humans Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2021 Document type: Article Affiliation country: Country of publication: